Solid Start to 2025
Envista delivered core growth of 0.2% and adjusted EBITDA margin around 13%, both in line with expectations, and adjusted EPS of $0.24, slightly ahead of expectations. Progress was also made on the $250 million share repurchase program.
Growth in Key Segments
Growth was delivered across consumables, Nobel Biocare, and Ormco (excluding China). Positive growth was also noted in North America, Japan, and emerging markets excluding China.
Operational Improvements
The company saw gains in customer service, price, G&A productivity, and Spark margins. Employee engagement improved by 4 points, and there was year-over-year improvement in employee retention.
Strong Cash Position
Envista maintains a strong balance sheet with net debt to adjusted EBITDA of approximately 1 times, providing flexibility during macroeconomic uncertainty.